Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0092-86 50242-0092 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 No Longer Used
50242-0094-90 50242-0094 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
50242-0094-47 50242-0094 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
71777-0390-01 71777-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
50419-0393-03 50419-0393 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Dec 6, 2022 In Use
50419-0391-01 50419-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
71777-0392-01 71777-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
50419-0390-01 50419-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
71777-0391-01 71777-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Jul 26, 2019 In Use
62856-0001-10 62856-0001 Altretamine Hexalen 50.0 mg/1 Chemotherapy Alkylating Agent Triazines Oral Dec 26, 1990 Dec 31, 2019 No Longer Used
65597-0801-01 65597-0801 Datopotamab Deruxtecan DATROWAY 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 Intravenous Jan 17, 2025 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec 20, 2019 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sep 20, 2021 In Use
31722-0258-28 31722-0258 LENALIDOMIDE LENALIDOMIDE 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
31722-0257-01 31722-0257 LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
00378-1941-01 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
59651-0345-01 59651-0345 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
43598-0514-21 43598-0514 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
60219-1716-02 60219-1716 Lenalidomide LENALIDOMIDE 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 12, 2025 In Use
59572-0415-00 59572-0415 Lenalidomide Revlimid 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jul 7, 2006 In Use
59651-0346-01 59651-0346 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
70377-0054-12 70377-0054 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2025 In Use
43598-0515-21 43598-0515 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
59651-0343-28 59651-0343 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use

Found 12159 results — Export these results